Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 4/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859886 | 0.86 | PDE4A (0.50) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL3679965 | 0.83 | ADORA2A (0.77) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL9263999 | 0.83 | AXL (0.48) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL24995357 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL2311045 | 0.81 | AXL (0.47) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL10171315 | 0.81 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL9381944 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL13660429 | 0.77 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL24996944 | 0.77 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BADORA3PDE4A | |
| SCHEMBL14513332 | 0.75 | ADORA2A (0.51) | ADORA2AADORA1ADORA2BADORA3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349861-B1 | THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| EP-0276057-B1 | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | MERCK & CO INC (US) | 1994-03-09 | — | — | EP | disclosed |
| US-4994464-A | Treatment of elevated intraocular pressure and glaucoma | MERCK & CO., INC. (US) | 1991-02-19 | — | — | US | disclosed |
| US-4889856-A | INTRAOCULAR PRESSURE REDUCTION; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0276057-A2 | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | MERCK & CO. INC. (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | CHRNA5, HTR5A, CHRNA6 | ADORA2A 6/4885ADORA1 37/4885ADORA2B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.